ARTICLE | Product Development

Oxford’s Landray wants RECOVERY-type trials to go well beyond COVID-19: a BioCentury audio interview

The co-creator of the U.K.’s adaptive platform trial sees uses in multiple other chronic diseases, public health priorities

September 10, 2020 2:00 AM UTC

Oxford University’s Martin Landray, one of the two initiators of the U.K.’s RECOVERY trial, said while the first consideration in designing the adaptive platform trial was to find a cure for COVID-19 as fast as possible, the second was to create a template that might spur activity in other public health diseases where drug development has faltered.

Landray, professor of medicine and epidemiology, created the RECOVERY trial with Oxford colleague Peter Horby. The trial, which recruited over 12,000 patients, produced three results in the first 100 days and continues to test other therapies for COVID-19...